🇺🇸 FDA
Patent

US 9890210

Antagonist antibodies directed against calcitonin gene-related peptide

granted A61KA61K2039/505A61K31/4045

Quick answer

US patent 9890210 (Antagonist antibodies directed against calcitonin gene-related peptide) held by TEVA PHARMACEUTICALS INTERNATIONAL GMBH expires Mon Feb 08 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
TEVA PHARMACEUTICALS INTERNATIONAL GMBH
Grant date
Tue Feb 13 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 08 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
15
CPC classes
A61K, A61K2039/505, A61K31/4045, A61K39/3955, A61P